Manage

Anthem Blue Cross

Prior Authorization requirements for Part B drugs: Exondys 51 (eteplirsen)

On July 1, 2017, Anthem Blue Cross prior authorization (PA) requirements will change for Part B Injectable/Infusible drugs covered by Anthem. The drug is Exondys 51 (eteplirsen). Federal and state law, as well as state contract language and CMS guidelines, including definitions and specific contract provisions/exclusions, take precedence over these precertification rules and must be considered first when determining coverage.

Non-compliance with new requirements may result in denied claims. Prior authorization requirements will be added to the following codes which is a drug billed with not otherwise classified (NOC) HCPCS J codes [J3490, J3590]:

- **Exondys 51 (eteplirsen):** For treatment of Duchenne muscular dystrophy (DMD). Specifically indicated for patients with confirmed mutation of the dystrophin gene amenable to exon 51 skipping. (C9484, J3490, J3590)

Please note, this drug is currently billed under the NOC J-codes [J3490, J3590]. Since this codes include drugs that are NOC, if the authorization is denied for medical necessity, the plan's denial will be for the drug and not the HCPCS.

Not all prior authorization requirements are listed here. Detailed prior authorization requirements are available to contracted providers by accessing the Provider Self-Service Tool at [www.Availity.com](http://www.Availity.com) at [https://www11.anthem.com/ca/home-providers.html](https://www11.anthem.com/ca/home-providers.html) > Login. Contracted and non-contracted providers who are unable to access Availity may call our Provider Services by calling the number on the back on the member's ID card for prior authorization requirements.

65092MUSENMUB 02/18/17

Anthem Blue Cross is the trade name of Blue Cross of California: Independent licensee of the Blue Cross Association. ® ANTHEM is a registered trademark of Anthem Insurance Companies, Inc. The Blue Cross names and symbols are registered marks of the Blue Cross Association.